Lords Mark AI Breast Cancer Tech Enters Final Clinical Trials

Lords Mark Industries Limited, in collaboration with C-MET, has advanced its AI-powered, radiation-free wearable breast cancer screening technology to the final clinical trial stage. Trials are planned across the USA, Great Britain, and Europe, with Phase 2 trials commencing in January 2027 targeting 98% accuracy. The company holds exclusive commercialization rights and aims for regulatory clearances and a commercial launch by April 2027. The technology uses thermal sensors and AI mapping for non-invasive detection and can be deployed in areas with limited electricity. Lords Mark is also seeking integration into national screening programs and insurance frameworks.